{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:12:54Z","timestamp":1791205974717,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jaad.2012.04.008","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T13:18:09Z","timestamp":1337347089000},"page":"1265-1272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study"],"prefix":"10.1016","volume":"67","author":[{"given":"Emily Y.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolyn A.","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Amaravadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia S.","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"McGettigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia R.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Schuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Seykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2012.04.008_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2012.04.008_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.04.008_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.008_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.008_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.008_bib6","doi-asserted-by":"crossref","unstructured":"Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol doi: 10.1111\/j.1468-3083.2012.04546.x. Published online April 28, 2012.","DOI":"10.1111\/j.1468-3083.2012.04546.x"},{"key":"10.1016\/j.jaad.2012.04.008_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.008_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2011.38.2895","article-title":"Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?","volume":"30","author":"Lacouture","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R germline variants confer risk for BRAF-mutant melanoma","volume":"313","author":"Landi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jaad.2012.04.008_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00000372-198000230-00017","article-title":"Subungual keratoacanthoma","volume":"2","author":"Stoll","year":"1980","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2012.04.008_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annder.2010.04.026","article-title":"Squamous cell carcinoma in a patient receiving sorafenib","volume":"138","author":"Adnot-Desanlis","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2012.04.008_bib15","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archdermatol.2010.395","article-title":"Invasive squamous cell carcinoma and sorafenib in a black patient","volume":"147","author":"Donaldson","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2012.04.008_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annder.2009.09.010","article-title":"Sorafenib-induced multiple eruptive keratoacanthomas","volume":"136","author":"Jantzem","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2012.04.008_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib22","first-page":"308","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib","volume":"10","author":"Lynch","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327480901600110","article-title":"Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene","volume":"16","author":"Marquez","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.jaad.2012.04.008_bib24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2012.04.008_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.jaad.2012.04.008_bib26","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdm221","article-title":"Sunitinib: bridging present and future cancer treatment","volume":"18","author":"Grimaldi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2012.04.008_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2012.04.008_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.04.008_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2012.04.008_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.04.008_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1","volume":"18","author":"Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2012.04.008_bib32","doi-asserted-by":"crossref","first-page":"21730","DOI":"10.1074\/jbc.273.34.21730","article-title":"The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes","volume":"273","author":"Ho","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2012.04.008_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-0004.2007.00743.x","article-title":"HRAS and the Costello syndrome","volume":"71","author":"Rauen","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.jaad.2012.04.008_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2133.2011.10744.x","article-title":"Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development","volume":"166","author":"Siegel","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib35","first-page":"521","article-title":"Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome","volume":"164","author":"Siegel","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib36","first-page":"1201","article-title":"Verrucous papules and\u00a0plaques in a pediatric patient: cutaneous papillomas associated with Costello syndrome","volume":"143","author":"Gonzalez","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.008_bib39","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS up-regulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.04.008_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-011-0198-4","article-title":"The \u201cSWOT\u201d of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?","volume":"13","author":"Nissan","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaad.2012.04.008_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.04.008_bib42","doi-asserted-by":"crossref","unstructured":"Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, et\u00a0al. Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Presented at: 2011 ASCO Annual Meeting; Chicago, IL.","DOI":"10.1200\/jco.2011.29.15_suppl.cra8503"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212004318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212004318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:24:48Z","timestamp":1759271088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962212004318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0190962212004318"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2012.04.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.06.045","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}